Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs

Rhea-AI Summary

Nexalin Technology (Nasdaq: NXL) appointed Dr. Robert Rothstein to its Scientific Advisory Board to support Alzheimer’s disease and traumatic brain injury (TBI) programs and to aid preparation of a Q-submission with the FDA later in 2025. Dr. Rothstein brings 40+ years of clinical and translational experience in emergency medicine, psychiatric care, and medical technology advisory roles.

Nexalin plans to initiate Alzheimer’s-specific trials in Q4 2025 and targets a TBI-focused submission thereafter, leveraging MEG-guided protocols, imaging biomarkers, and expanded SAB oversight.

Positive

• Dr. Rothstein appointment adds 40+ years clinical experience
• Q-submission support for FDA meeting planned later in 2025
• Alzheimer’s-specific trials scheduled to start in Q4 2025
• TBI-focused submission targeted after Q4 2025
• MEG-guided protocols and imaging biomarkers will underpin trials

Negative

• None.

Insights

Clinical-regulatory strategist

Appointment strengthens clinical and regulatory readiness ahead of planned FDA engagement and Q4 2025 Alzheimer’s trial start.

Nexalin adds a senior clinical voice with deep emergency‑psychiatry and translational research experience to its Scientific Advisory Board, which directly supports preparation of a Q‑submission and a planned FDA meeting later this year. The hire aligns with the company’s stated push toward Alzheimer’s and military TBI programs and may improve design rigor for upcoming protocols that rely on imaging biomarkers and MEG guidance.

Key dependencies and risks center on regulator feedback, trial design quality, and whether the internal and published data the company references meet FDA expectations for clinical endpoints and safety. An advisory appointment does not change clinical evidence; the impact depends on subsequent concrete filings, the FDA response to the Q‑submission, and execution of the trials.

Watch for the company to file the Q‑submission and for trial initiation in Q4 2025, plus any FDA meeting minutes or formal feedback within weeks to months after that meeting. These milestones will determine whether this advisory addition translates into measurable regulatory or clinical progress.

HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Dr. Robert Rothstein, a pioneering expert in mental healthcare, to its Scientific Advisory Board (SAB). This addition reinforces Nexalin’s strategic focus on the global mental healthcare crisis, including the treatment of Alzheimer’s disease and Traumatic Brain Injury (TBI). In anticipation of the Company’s new FDA submissions, Dr. Rothstein will support Nexalin’s preparation of its Q-submission for a meeting with the FDA later this year.

Dr. Rothstein brings more than four decades of clinical, academic, and leadership experience in emergency medicine, mental health interventions, and translational research. He has served in senior roles at prestigious institutions including the University of Chicago, Harbor/UCLA Medical Center, and Suburban Hospital/Johns Hopkins Medicine. His work spans urgent psychiatric care, trauma management, and advisory roles across numerous clinical-stage startups, making him uniquely qualified to support Nexalin’s expanding footprint in neuropsychiatric therapeutics.

“We are honored to welcome Dr. Rothstein to our Scientific Advisory Board,” said Mark White, CEO of Nexalin Technology. “His unparalleled experience in emergency medicine and mental health crisis management brings a vital clinical perspective as we accelerate our Alzheimer’s and military TBI programs. With FDA submission milestones on the horizon, Dr. Rothstein’s leadership will help shape our clinical designs and support our regulatory strategy.”

This SAB expansion follows the May 2025 reconstitution of the board to align with Nexalin’s enhanced focus on Alzheimer’s disease. With promising internal and published data supporting DIFS™’s potential to stimulate deep brain regions associated with memory and executive function, Nexalin is intensifying its efforts in neurodegenerative research. Concurrently, the Company is escalating development in TBI—particularly within military populations—where early research suggests DIFS™ may improve recovery and resilience following brain trauma.

“The scientific opportunity at Nexalin lies at the intersection of bioelectronic medicine and unmet neuropsychiatric needs,” said Dr. Rothstein. “I’m particularly excited about the potential of this non-invasive technology in Alzheimer’s care, where neuromodulation could provide functional benefits without pharmaceutical side effects. Additionally, the application of Nexalin’s therapy in traumatic brain injury—especially among military service members—is a critical mission I’m proud to support.”

Dr. Rothstein’s distinguished career includes service on the Board of the American Board of Emergency Medicine, editorial leadership across leading journals, including Annals of Emergency Medicine, and extensive publication in the areas of cardiac trauma, psychiatric evaluation, and integrative emergency care. He has also chaired and advised multiple medical technology companies, offering cross-disciplinary insight that bridges clinical innovation with practical implementation.

With his addition, Nexalin’s SAB is now better positioned to guide the Company’s expanding clinical portfolio. Nexalin anticipates initiating Alzheimer’s-specific trials in Q4 2025, with a TBI-focused submission targeted thereafter. These efforts will be underpinned by robust imaging biomarkers, MEG-guided protocols, and rigorous trial oversight by the SAB.

About Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.

FORWARD-LOOKING STATEMENTS

This press release contains statements that constitute "forward-looking statements," These statements relate to future events or Nexalin’s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that Nexalin or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or Nexalin’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's Report on Form 10-K for the year ended December 31, 2024 and other filings as filed with the Securities and Exchange Commission. Copies of such filings are available on the SEC's website, www.sec.gov. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:

Crescendo Communications, LLC
Tel: (212) 671-1020
Email: NXL@crescendo-ir.com

FAQ

Who did Nexalin (NXL) add to its Scientific Advisory Board on October 13, 2025?

Dr. Robert Rothstein, a clinician and translational researcher with 40+ years of experience in emergency medicine and mental healthcare.

How will Dr. Rothstein support Nexalin’s FDA interactions for NXL in 2025?

He will help prepare Nexalin’s Q-submission and advise on clinical design and regulatory strategy ahead of a planned FDA meeting later in 2025.

When will Nexalin (NXL) begin Alzheimer’s-specific clinical trials?

Nexalin anticipates initiating Alzheimer’s-specific trials in Q4 2025.

What is Nexalin’s timeline for its TBI program and submissions for NXL?

The company targets a TBI-focused submission after the Q4 2025 Alzheimer’s trial start.

What trial methods will Nexalin (NXL) use for its neurodegenerative and TBI studies?

Trials will use imaging biomarkers and MEG-guided protocols with SAB oversight.

Does Nexalin (NXL) describe clinical data supporting DIFS for Alzheimer’s and TBI?

The company cites promising internal and published data suggesting DIFS may stimulate deep brain regions tied to memory and recovery.